Over the last three to five years, FUJIFILM India's healthcare business has delivered strong double-digit growth

Koji Wada, MD, FUJIFILM India Healthcare discusses the company's growth plans and its vision for inclusive, technology-driven healthcare in India. He shares insights on how Al, localisation and partnerships are reshaping access and innovation across India's evolving medtech landscape, in an exclusive interview with Lakshmipriya Nair

- 

India's medtech sector is clearly full of promise. But what do you see as the biggest opportunities and risks on the horizon?

India's medtech sector is indeed full of promise, and we see tremendous opportunities on the horizon. Domestic manufacturing is at the forefront, with government initiatives like the PLI scheme creating a strong ecosystem for local production of both consumables and advanced diagnostic equipment. This aligns well with our own long-term "Make in India" vision. The integration of digital health and AI-powered diagnostics represents another major opportunity, enabling early detection, improved accuracy, and affordable access, particularly in Tier 2 and Tier 3 cities where FUJIFILM India has already built scale, with over 79,000 imaging systems and strong service support. While there is immense potential of growth, at the same time, the sector must navigate certain challenges. Regulatory frameworks for AI-based healthcare are still evolving, and clarity on data governance and privacy will be critical to ensuring trust. As digital devices proliferate, cybersecurity and supply chain resilience require sustained focus. We see these not as obstacles but as opportunities for closer collaboration between industry, government, and academia. By strengthening quality standards, enhancing local capabilities, and investing in talent, India can address these challenges and set global benchmarks. For FUJIFILM India, our commitment remains to bring innovative, AI-enabled, and inclusive healthcare solutions that support India's ambition of becoming a world leader in medtech.

India has a mix of strong homegrown manufacturers and global players like Fujifilm. How can international companies contribute to shaping the ecosystem here without overshadowing local innovation?